Albert Labs’ Daniel Sanders explains its partnership with the University of CESPU health sciences department in Portugal.
Toxicology is hugely important in pre-clinical drug stages, he says and through the partnership Albert Labs will be establishing good laboratory practices within CESPU’s facility and be able to monitor all aspects of toxicology during pre-clinical trials.
Dr Michael Raymont, chief executive of Albert Labs, spoke to Proactive about the toxicology research for KRN-101.Â
KRN-101 is a psilocybin-based drug, and is used as a treatment for cancer-related anxiety.Â
Dr Raymont said the company is getting ready to trial this in the Autumn, and investors should know it is making steady progress.
